825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP
Abstract Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on o...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv286-iv287 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | iv287 |
|---|---|
| container_issue | suppl_4 |
| container_start_page | iv286 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | Gravis, G. Chanez, B. Derosa, L. Beuselinck, B. Laguerre, B. Barthelemy, P. Brachet, P.E. Lobbedez, F. Joly Escudier, B. Stewart, G.D. Harrison, D. Laird, A. Vasudev, N. Ralph, C. Larkin, J. Lote, H. Walz, J. Thomassin, J. Salem, N. Boher, J.M. |
| description | Abstract
Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on overall survival (OS).
Methods: Data were collected from mRCC pts with GM or non-GM at metastatic presentation. GM: pts with at least one GM with or without other sites. Non-GM: pts without GM at metastatic presentation. Pts were treated in 5 French, 1 Belgian and 3 UK centers between January 2004 and October 2013. Association between OS and site of metastasis was assessed using the log-rank test for univariate analysis and the chi-square test for multivariable Cox regression.
Results: 188 GM and 453 non-GM mRCC pts were analyzed. The majority were male (70.2%), median age was 59y, with no difference between the GM and non-GM groups. Interval from diagnosis to metastasis was 25.7 months (mo) (0.03-272.8)for GM and 4.8 mo (0.03-334) for non-GM (p < 0.001). 39% GM pts were MSKCC favorable risk compared with 23% non-GM pts (p |
| doi_str_mv | 10.1093/annonc/mdu337.18 |
| format | Article |
| fullrecord | <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdu337_18</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdu337.18</oup_id><sourcerecordid>10.1093/annonc/mdu337.18</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdu337_183</originalsourceid><addsrcrecordid>eNqVkMtqwzAQRUVpoe5j3-XsixPJihN7qapyLJAlI8nuUpg-oKVxQkwW_Zl-a-2m-YDCwAzcwx04CN0RPCM4p_Ou77f983zzcqB0NSPZGYpIuszjDC_IOYpwntB4ldLFJboahg-M8TJP8gh9Z0lay6pm3IPRYFphmVLgGtvKlikwBawV04-NYhYq4ZkbRzqQGmrmpdDewZP05SnzkgNXYoS5GHus0GPJ78mZ5VKbis2mRw-iZKqY6n0pTpg1zgEvmdZCwdqapr5BF2_d5_B6-7ev0X0hPC_j7WEXdvv3Tbf_CgSHSUE4KghHBYFk9H_0Dyp3WVo</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gravis, G. ; Chanez, B. ; Derosa, L. ; Beuselinck, B. ; Laguerre, B. ; Barthelemy, P. ; Brachet, P.E. ; Lobbedez, F. Joly ; Escudier, B. ; Stewart, G.D. ; Harrison, D. ; Laird, A. ; Vasudev, N. ; Ralph, C. ; Larkin, J. ; Lote, H. ; Walz, J. ; Thomassin, J. ; Salem, N. ; Boher, J.M.</creator><creatorcontrib>Gravis, G. ; Chanez, B. ; Derosa, L. ; Beuselinck, B. ; Laguerre, B. ; Barthelemy, P. ; Brachet, P.E. ; Lobbedez, F. Joly ; Escudier, B. ; Stewart, G.D. ; Harrison, D. ; Laird, A. ; Vasudev, N. ; Ralph, C. ; Larkin, J. ; Lote, H. ; Walz, J. ; Thomassin, J. ; Salem, N. ; Boher, J.M.</creatorcontrib><description><![CDATA[Abstract
Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on overall survival (OS).
Methods: Data were collected from mRCC pts with GM or non-GM at metastatic presentation. GM: pts with at least one GM with or without other sites. Non-GM: pts without GM at metastatic presentation. Pts were treated in 5 French, 1 Belgian and 3 UK centers between January 2004 and October 2013. Association between OS and site of metastasis was assessed using the log-rank test for univariate analysis and the chi-square test for multivariable Cox regression.
Results: 188 GM and 453 non-GM mRCC pts were analyzed. The majority were male (70.2%), median age was 59y, with no difference between the GM and non-GM groups. Interval from diagnosis to metastasis was 25.7 months (mo) (0.03-272.8)for GM and 4.8 mo (0.03-334) for non-GM (p < 0.001). 39% GM pts were MSKCC favorable risk compared with 23% non-GM pts (p <0.0001) and 6.7% GM pts were MSKCC poor risk vs 16.7% non-GM. Fuhrman grade was I/II in 48.7% GM pts and 33.6% in the non-GM (p = 0.005). Median follow-up was 82.4 mo (68.9-89.5). Median OS was 64.8 mo (52.7-86) for GM and 39.8 mo (34.8-46.1) for non-GM (HR = 1.66 [95% CI = 1.32-2.1], p < 0.001). Age (<60y vs >60y), delay between renal tumor and metastatic diagnosis, MSKCC risk group and GM or non-GM group were significant parameters in univariate OS analysis (p < 0.001). In a multivariate analysis adjusted according to MSKCC risk group, GM status was a strong prognostic factor (HR = 0.76 [95% CI = 0.59-0.98], p < 0.035).
Conclusions: This large retrospective study shows that the presence of at least one GM at metastatic presentation of clear cell mRCC was associated with a significantly longer OS compared to non-GM pts. The presence of GM vs non-GM disease was an independent prognostic factor for OS. Further translational studies will be performed on matched primary tumor and metastasis samples to assess molecular differences between GM and non-GM.
Disclosure: All authors have declared no conflicts of interest.]]></description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdu337.18</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv286-iv287</ispartof><rights>European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Gravis, G.</creatorcontrib><creatorcontrib>Chanez, B.</creatorcontrib><creatorcontrib>Derosa, L.</creatorcontrib><creatorcontrib>Beuselinck, B.</creatorcontrib><creatorcontrib>Laguerre, B.</creatorcontrib><creatorcontrib>Barthelemy, P.</creatorcontrib><creatorcontrib>Brachet, P.E.</creatorcontrib><creatorcontrib>Lobbedez, F. Joly</creatorcontrib><creatorcontrib>Escudier, B.</creatorcontrib><creatorcontrib>Stewart, G.D.</creatorcontrib><creatorcontrib>Harrison, D.</creatorcontrib><creatorcontrib>Laird, A.</creatorcontrib><creatorcontrib>Vasudev, N.</creatorcontrib><creatorcontrib>Ralph, C.</creatorcontrib><creatorcontrib>Larkin, J.</creatorcontrib><creatorcontrib>Lote, H.</creatorcontrib><creatorcontrib>Walz, J.</creatorcontrib><creatorcontrib>Thomassin, J.</creatorcontrib><creatorcontrib>Salem, N.</creatorcontrib><creatorcontrib>Boher, J.M.</creatorcontrib><title>825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP</title><title>Annals of oncology</title><description><![CDATA[Abstract
Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on overall survival (OS).
Methods: Data were collected from mRCC pts with GM or non-GM at metastatic presentation. GM: pts with at least one GM with or without other sites. Non-GM: pts without GM at metastatic presentation. Pts were treated in 5 French, 1 Belgian and 3 UK centers between January 2004 and October 2013. Association between OS and site of metastasis was assessed using the log-rank test for univariate analysis and the chi-square test for multivariable Cox regression.
Results: 188 GM and 453 non-GM mRCC pts were analyzed. The majority were male (70.2%), median age was 59y, with no difference between the GM and non-GM groups. Interval from diagnosis to metastasis was 25.7 months (mo) (0.03-272.8)for GM and 4.8 mo (0.03-334) for non-GM (p < 0.001). 39% GM pts were MSKCC favorable risk compared with 23% non-GM pts (p <0.0001) and 6.7% GM pts were MSKCC poor risk vs 16.7% non-GM. Fuhrman grade was I/II in 48.7% GM pts and 33.6% in the non-GM (p = 0.005). Median follow-up was 82.4 mo (68.9-89.5). Median OS was 64.8 mo (52.7-86) for GM and 39.8 mo (34.8-46.1) for non-GM (HR = 1.66 [95% CI = 1.32-2.1], p < 0.001). Age (<60y vs >60y), delay between renal tumor and metastatic diagnosis, MSKCC risk group and GM or non-GM group were significant parameters in univariate OS analysis (p < 0.001). In a multivariate analysis adjusted according to MSKCC risk group, GM status was a strong prognostic factor (HR = 0.76 [95% CI = 0.59-0.98], p < 0.035).
Conclusions: This large retrospective study shows that the presence of at least one GM at metastatic presentation of clear cell mRCC was associated with a significantly longer OS compared to non-GM pts. The presence of GM vs non-GM disease was an independent prognostic factor for OS. Further translational studies will be performed on matched primary tumor and metastasis samples to assess molecular differences between GM and non-GM.
Disclosure: All authors have declared no conflicts of interest.]]></description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkMtqwzAQRUVpoe5j3-XsixPJihN7qapyLJAlI8nuUpg-oKVxQkwW_Zl-a-2m-YDCwAzcwx04CN0RPCM4p_Ou77f983zzcqB0NSPZGYpIuszjDC_IOYpwntB4ldLFJboahg-M8TJP8gh9Z0lay6pm3IPRYFphmVLgGtvKlikwBawV04-NYhYq4ZkbRzqQGmrmpdDewZP05SnzkgNXYoS5GHus0GPJ78mZ5VKbis2mRw-iZKqY6n0pTpg1zgEvmdZCwdqapr5BF2_d5_B6-7ev0X0hPC_j7WEXdvv3Tbf_CgSHSUE4KghHBYFk9H_0Dyp3WVo</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Gravis, G.</creator><creator>Chanez, B.</creator><creator>Derosa, L.</creator><creator>Beuselinck, B.</creator><creator>Laguerre, B.</creator><creator>Barthelemy, P.</creator><creator>Brachet, P.E.</creator><creator>Lobbedez, F. Joly</creator><creator>Escudier, B.</creator><creator>Stewart, G.D.</creator><creator>Harrison, D.</creator><creator>Laird, A.</creator><creator>Vasudev, N.</creator><creator>Ralph, C.</creator><creator>Larkin, J.</creator><creator>Lote, H.</creator><creator>Walz, J.</creator><creator>Thomassin, J.</creator><creator>Salem, N.</creator><creator>Boher, J.M.</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20140901</creationdate><title>825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP</title><author>Gravis, G. ; Chanez, B. ; Derosa, L. ; Beuselinck, B. ; Laguerre, B. ; Barthelemy, P. ; Brachet, P.E. ; Lobbedez, F. Joly ; Escudier, B. ; Stewart, G.D. ; Harrison, D. ; Laird, A. ; Vasudev, N. ; Ralph, C. ; Larkin, J. ; Lote, H. ; Walz, J. ; Thomassin, J. ; Salem, N. ; Boher, J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdu337_183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gravis, G.</creatorcontrib><creatorcontrib>Chanez, B.</creatorcontrib><creatorcontrib>Derosa, L.</creatorcontrib><creatorcontrib>Beuselinck, B.</creatorcontrib><creatorcontrib>Laguerre, B.</creatorcontrib><creatorcontrib>Barthelemy, P.</creatorcontrib><creatorcontrib>Brachet, P.E.</creatorcontrib><creatorcontrib>Lobbedez, F. Joly</creatorcontrib><creatorcontrib>Escudier, B.</creatorcontrib><creatorcontrib>Stewart, G.D.</creatorcontrib><creatorcontrib>Harrison, D.</creatorcontrib><creatorcontrib>Laird, A.</creatorcontrib><creatorcontrib>Vasudev, N.</creatorcontrib><creatorcontrib>Ralph, C.</creatorcontrib><creatorcontrib>Larkin, J.</creatorcontrib><creatorcontrib>Lote, H.</creatorcontrib><creatorcontrib>Walz, J.</creatorcontrib><creatorcontrib>Thomassin, J.</creatorcontrib><creatorcontrib>Salem, N.</creatorcontrib><creatorcontrib>Boher, J.M.</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gravis, G.</au><au>Chanez, B.</au><au>Derosa, L.</au><au>Beuselinck, B.</au><au>Laguerre, B.</au><au>Barthelemy, P.</au><au>Brachet, P.E.</au><au>Lobbedez, F. Joly</au><au>Escudier, B.</au><au>Stewart, G.D.</au><au>Harrison, D.</au><au>Laird, A.</au><au>Vasudev, N.</au><au>Ralph, C.</au><au>Larkin, J.</au><au>Lote, H.</au><au>Walz, J.</au><au>Thomassin, J.</au><au>Salem, N.</au><au>Boher, J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP</atitle><jtitle>Annals of oncology</jtitle><date>2014-09-01</date><risdate>2014</risdate><volume>25</volume><issue>suppl_4</issue><spage>iv286</spage><epage>iv287</epage><pages>iv286-iv287</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract><![CDATA[Abstract
Aim: Glandular metastasis (GM) as defined by pancreas, breast, parotid, thyroid and contralateral adrenal metastasis are rare in clear cell renal cell carcinoma. We have performed a multicenter comparison of metastatic clear cell RCC (mRCC) with GM and non-GM to determine if GM impacts on overall survival (OS).
Methods: Data were collected from mRCC pts with GM or non-GM at metastatic presentation. GM: pts with at least one GM with or without other sites. Non-GM: pts without GM at metastatic presentation. Pts were treated in 5 French, 1 Belgian and 3 UK centers between January 2004 and October 2013. Association between OS and site of metastasis was assessed using the log-rank test for univariate analysis and the chi-square test for multivariable Cox regression.
Results: 188 GM and 453 non-GM mRCC pts were analyzed. The majority were male (70.2%), median age was 59y, with no difference between the GM and non-GM groups. Interval from diagnosis to metastasis was 25.7 months (mo) (0.03-272.8)for GM and 4.8 mo (0.03-334) for non-GM (p < 0.001). 39% GM pts were MSKCC favorable risk compared with 23% non-GM pts (p <0.0001) and 6.7% GM pts were MSKCC poor risk vs 16.7% non-GM. Fuhrman grade was I/II in 48.7% GM pts and 33.6% in the non-GM (p = 0.005). Median follow-up was 82.4 mo (68.9-89.5). Median OS was 64.8 mo (52.7-86) for GM and 39.8 mo (34.8-46.1) for non-GM (HR = 1.66 [95% CI = 1.32-2.1], p < 0.001). Age (<60y vs >60y), delay between renal tumor and metastatic diagnosis, MSKCC risk group and GM or non-GM group were significant parameters in univariate OS analysis (p < 0.001). In a multivariate analysis adjusted according to MSKCC risk group, GM status was a strong prognostic factor (HR = 0.76 [95% CI = 0.59-0.98], p < 0.035).
Conclusions: This large retrospective study shows that the presence of at least one GM at metastatic presentation of clear cell mRCC was associated with a significantly longer OS compared to non-GM pts. The presence of GM vs non-GM disease was an independent prognostic factor for OS. Further translational studies will be performed on matched primary tumor and metastasis samples to assess molecular differences between GM and non-GM.
Disclosure: All authors have declared no conflicts of interest.]]></abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdu337.18</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv286-iv287 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_oup_primary_10_1093_annonc_mdu337_18 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | 825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA. ON BEHALF OF THE RENAL CROSS CHANNEL GROUP |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A35%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=825PIMPACT%20ON%20OVERALL%20SURVIVAL%20OF%20GLANDULAR%20METASTASIS%20IN%20PATIENTS%20WITH%20METASTATIC%20CLEAR%20CELL%20RENAL%20CELL%20CARCINOMA.%20ON%20BEHALF%20OF%20THE%20RENAL%20CROSS%20CHANNEL%20GROUP&rft.jtitle=Annals%20of%20oncology&rft.au=Gravis,%20G.&rft.date=2014-09-01&rft.volume=25&rft.issue=suppl_4&rft.spage=iv286&rft.epage=iv287&rft.pages=iv286-iv287&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdu337.18&rft_dat=%3Coup%3E10.1093/annonc/mdu337.18%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdu337.18&rfr_iscdi=true |